Home > BRISA > Search result
COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 2

Bedaquilina para pacientes com tuberculose resistentes à rifampicina, multirresistentes e extensivamente resistentes a medicamentos

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde.
INTRODUÇÃO: A tuberculose (TB), conhecida anteriormente como tísica, é uma doença que pode ser causada por sete espécies do gênero do complexo Mycobacterium sendo a mais importante, do ponto de vista de saúde pública, a M. tuberculosis. Globalmente cerca de 10 milhões de pessoas tiveram TB no a...
Tuberculosis, Multidrug-Resistant/drug therapy, Diarylquinolines/therapeutic use, Levofloxacin/therapeutic use, Moxifloxacin/therapeutic use, Amikacin/therapeutic use, Capreomycin/therapeutic use, Ethionamide/therapeutic use, Linezolid/therapeutic use, Clofazimine/therapeutic use, Pyrazinamide/therapeutic use, Isoniazid/therapeutic use, Rifampin/therapeutic use, Aminosalicylic Acid/therapeutic use, Technology Assessment, Biomedical, Cost-Benefit Analysis/economics, Unified Health System, Brazil
Fulltext

Informe diário de evidências COVID-19: busca realizada em 17 de julho de 2020

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde.
O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao d...
Coronavirus Infections/drug therapy, Pneumonia, Viral/drug therapy, Betacoronavirus/drug effects, Hydroxychloroquine/therapeutic use, Azithromycin/therapeutic use, Lopinavir/therapeutic use, Ritonavir/therapeutic use, Adrenal Cortex Hormones/therapeutic use, Darunavir/therapeutic use, Cobicistat/therapeutic use, Interferon beta-1a/therapeutic use, Ganciclovir/therapeutic use, Oseltamivir/therapeutic use, Meropenem/therapeutic use, Linezolid/therapeutic use, Ribavirin/therapeutic use, Dexamethasone/therapeutic use, Vancomycin/therapeutic use, Cefepime/therapeutic use, Adrenergic beta-1 Receptor Antagonists/therapeutic use, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Adalimumab/therapeutic use, Etanercept/therapeutic use, Abatacept/therapeutic use, Cohort Studies, Technology Assessment, Biomedical
Fulltext